Pharma Pulse: Child Vaccines Show Adult Protection, Lilly Pauses Mounjaro Shipments, and FDA Rejects Lytenava Resubmission

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering new research on vaccine protection, Eli Lilly’s pause in UK shipments of Mounjaro, and the FDA’s response to Outlook Therapeutics’ eye drug resubmission.

• New research shows that the PCV10 pneumococcal vaccine, given to children, provides significant indirect protection to unvaccinated adults. The study highlights reduced transmission and improved community-wide immunity, underscoring the broader public health impact of pediatric vaccination programs. Experts say this strengthens the case for continued investment in childhood immunization as a tool for protecting vulnerable adult populations.
• In other news, Eli Lilly has temporarily paused shipments of Mounjaro in the United Kingdom after a potential 170% price increase drew scrutiny. The move raises concerns about patient access, particularly through the National Health Service, which may struggle with affordability at the new price point. With demand for GLP-1 therapies rising worldwide, the decision reflects the ongoing tension between drug pricing, value, and access in obesity and diabetes care.
• Lastly, Outlook Therapeutics has received a Complete Response Letter from the FDA for its resubmitted biologics license application for Lytenava, an ophthalmic bevacizumab for wet age-related macular degeneration. The agency cited concerns around manufacturing and quality, delaying approval once again. Outlook says it remains committed to addressing FDA’s requirements, but the setback highlights the challenges smaller biotech firms face in bringing ophthalmology biosimilars to market.

From community-wide vaccine benefits to pricing battles in obesity drugs and regulatory hurdles in ophthalmology, these stories highlight the diverse forces shaping today’s pharmaceutical industry.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.